The introduction of bisphosphonates in oncology has substantially broadened the therapeutic spectrum in the treatment of osseous manifestations of malignant diseases. In particular, in patients with breast cancer and multiple myeloma bisphosphonates are able to prevent the occurrence of skeletal complications in certain clinical situations. However, several questions remain unanswered, notably regarding the value of bisphosphonates for subgroups of patients and the optimal duration of therapy. In other tumor types the data on bisphosphonates is much less clear which precludes the formulation of guidelines for their clinical use until reliable information based on prospective clinical trials becomes available. The increased activity of novel bisphosphonates such as ibandronate and zoledronate may in the future open the field for innovative applications of these drugs in oncology.
|Translated title of the contribution||Current status of bisphosphonate therapy in hemato-oncology|
|Number of pages||9|
|State||Published - Jan 1 2002|
- Breast cancer
- Multiple myeloma
ASJC Scopus subject areas
- Internal Medicine